[Recommendations for inhaled nitric oxide treatment in the newborn].
The recommendations in this document describe the current indications for inhaled nitric oxide (iNO) treatment in the newborn and clearly distinguish between those supported by scientific evidence and those for which evidence is still lacking, such as its use in preterm infants. The methodology for iNO administration, its dosage and the main secondary effects are discussed, and the reasons for lack of response to this treatment are analyzed.
Figueras Aloy
J
J
Hospital Clínico, Instituto Clínico de Ginecología, Obstetricia y Neonatología, Unidad Integrada de Pediatría, Universidad de Barcelona, Spain. jfiguer@clinic.ub.es
Castillo Salinas
F
F
Elorza Fernández
D
D
Sánchez-Luna
M
M
Pérez Rodríguez
J
J
D000280:Administration, Inhalation; D045462:Endothelium-Dependent Relaxing Factors / Q000008:administration & dosage; D006330:Heart Defects, Congenital; D065630:Hernias, Diaphragmatic, Congenital; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000628:therapy*; D007234:Infant, Premature; D009569:Nitric Oxide / Q000008:administration & dosage*; D010547:Persistent Fetal Circulation Syndrome; D012127:Respiratory Distress Syndrome, Newborn
D045462:Endothelium-Dependent Relaxing Factors; D009569:Nitric Oxide